CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net income	$ 26,011	$ 47,110
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred taxes	2,895	12,953
Depreciation of fixed assets and amortization of intangible assets	61,095	15,478
Amortization of debt issuance costs	2,957	1,976
Amortization of debt discount	2,107	17,245
Loss (gain) on disposal of fixed assets	193	(10)
Stock-based compensation	35,415	31,356
Changes in contingent consideration	(23,394)	(2,147)
Impairment of investment	10,000	0
Loss on investment	184	2,641
Changes in operating assets and liabilities:
Accounts receivable, net	2,847	3,070
Inventories, net	1,751	(2,560)
Prepaid expenses and other assets	(568)	907
Accounts payable	4,681	(825)
Accrued expenses and income taxes payable	(23,560)	(17,034)
Other liabilities	623	(1,996)
Payment of contingent consideration	0	(5,662)
Net cash provided by operating activities	103,237	102,502
Investing activities:
Purchases of fixed assets	(24,584)	(36,700)
Purchases of available-for-sale investments	(319,426)	(513,492)
Sales of available-for-sale investments	152,636	470,614
Payment of contingent consideration	(32,000)	0
Purchases of equity and debt investments	(13,000)	(17,187)
Sale of equity investment	0	9,057
Net cash used in investing activities	(236,374)	(87,708)
Financing activities:
Proceeds from exercises of stock options	23,482	19,049
Proceeds from shares issued under employee stock purchase plan	1,820	1,574
Repayment of Term loan B facility maturing December 2026	(18,750)	0
Payment of contingent consideration to MyoScience, Inc. securityholders	0	(1,338)
Net cash (used in) provided by financing activities	(343,017)	19,285
Net (decrease) increase in cash and cash equivalents	(476,154)	34,079
Cash and cash equivalents, beginning of period	585,578	99,957
Cash and cash equivalents, end of period	109,424	134,036
Supplemental cash flow information:
Cash paid for interest	23,620	5,096
Cash paid for income taxes, net of refunds	4,216	2,259
Non-cash investing and financing activities:
Issuance of common stock from conversion of 2022 convertible senior notes	3,040	0
Fixed assets included in accounts payable and accrued liabilities	5,486	4,719
Convertible Senior Notes Due 2022
Financing activities:
Repayment of convertible senior notes	(156,960)	0
Convertible Senior Notes Due 2024
Financing activities:
Repayment of convertible senior notes	$ (192,609)	$ 0